[go: up one dir, main page]

WO2010047509A3 - Anticorps dirigé contre le dr5 présentant une meilleure affinité et une meilleure stabilité, et composition destinée a prévenir ou traiter le cancer et contenant cet anticorps - Google Patents

Anticorps dirigé contre le dr5 présentant une meilleure affinité et une meilleure stabilité, et composition destinée a prévenir ou traiter le cancer et contenant cet anticorps Download PDF

Info

Publication number
WO2010047509A3
WO2010047509A3 PCT/KR2009/006036 KR2009006036W WO2010047509A3 WO 2010047509 A3 WO2010047509 A3 WO 2010047509A3 KR 2009006036 W KR2009006036 W KR 2009006036W WO 2010047509 A3 WO2010047509 A3 WO 2010047509A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
chain variable
variable region
stability
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/006036
Other languages
English (en)
Korean (ko)
Other versions
WO2010047509A2 (fr
WO2010047509A9 (fr
Inventor
김용성
권명희
이승현
박경진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajou University Industry Academic Cooperation Foundation
Original Assignee
Ajou University Industry Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020090066518A external-priority patent/KR101117070B1/ko
Application filed by Ajou University Industry Academic Cooperation Foundation filed Critical Ajou University Industry Academic Cooperation Foundation
Publication of WO2010047509A2 publication Critical patent/WO2010047509A2/fr
Publication of WO2010047509A9 publication Critical patent/WO2010047509A9/fr
Publication of WO2010047509A3 publication Critical patent/WO2010047509A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un anticorps dirigé contre le DR5 présentant une meilleure affinité et une meilleure stabilité, qui se lie spécifiquement au récepteur de mort 5 (DR5) pour détruire efficacement des cellules cancéreuses. Cette invention se rapporte également à une composition destinée à prévenir ou traiter le cancer, qui contient ledit anticorps. Cet anticorps dirigé contre le DR5 provoque des mutagenèses dans les résidus amino-acides de VH-CDR2 and VH-CDR3 au sein de la région variable de la chaîne lourde et dans les résidus amino-acides de VL-CDR3 dans la région variable de la chaîne légère de HW1 qui est ledit anticorps dirigé contre le DR5, et remplace la charpente au sein de la région variable de la chaîne lourde de manière à passer d'un sous-type VH6 à un sous-type VH3 et remplace la charpente au sein de la région variable de la chaîne légère par la partie de charpente Vk1 ou Vk3 de manière à obtenir une meilleure affinité et une meilleure stabilité pour ledit anticorps dirigé contre le DR5, HW1. En outre, cet anticorps dirigé contre le DR5 induit efficacement l'apoptose par rapport à des cellules cancéreuses sensibles au TRAIL qui expriment le DR5 et des cellules cancéreuses résistantes au TRAIL qui expriment le DR5 par autophagie, de sorte que cet anticorps puisse être employé utilement pour empêcher ou traiter des cancers provoqués par l'expression du DR5.
PCT/KR2009/006036 2008-10-24 2009-10-20 Anticorps dirigé contre le dr5 présentant une meilleure affinité et une meilleure stabilité, et composition destinée a prévenir ou traiter le cancer et contenant cet anticorps Ceased WO2010047509A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20080104737 2008-10-24
KR10-2008-0104737 2008-10-24
KR10-2009-0066518 2009-07-21
KR1020090066518A KR101117070B1 (ko) 2008-10-24 2009-07-21 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물

Publications (3)

Publication Number Publication Date
WO2010047509A2 WO2010047509A2 (fr) 2010-04-29
WO2010047509A9 WO2010047509A9 (fr) 2010-09-02
WO2010047509A3 true WO2010047509A3 (fr) 2010-10-21

Family

ID=42119820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006036 Ceased WO2010047509A2 (fr) 2008-10-24 2009-10-20 Anticorps dirigé contre le dr5 présentant une meilleure affinité et une meilleure stabilité, et composition destinée a prévenir ou traiter le cancer et contenant cet anticorps

Country Status (1)

Country Link
WO (1) WO2010047509A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
KR101796277B1 (ko) 2016-04-12 2017-11-13 앱클론(주) 안정성이 개선된 ｈｅｒ２에 특이적으로 결합하는 항체
KR102201992B1 (ko) * 2016-09-08 2021-01-12 주식회사 우리기술 clec14a에 특이적으로 결합하는 탈당화 항체 및 그 용도
KR101926834B1 (ko) * 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
CN109837243A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种敲除pd1的靶向dr5的嵌合抗原受体t细胞及其制备方法和应用
BR112021001188A8 (pt) 2018-07-23 2022-12-06 Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases Composição que contém vacina contra a influenza
BR112021017310A8 (pt) 2019-03-04 2022-12-06 Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases Método para produzir vacina fracionada de ha de influenza
TWI756870B (zh) * 2019-10-17 2022-03-01 財團法人國家衛生研究院 琥珀酸作為用於癌症診斷和治療之生物標記的用途
CN113501876B (zh) * 2021-07-16 2022-10-18 四川大学华西医院 一种特异性结合蛋白激酶p38δ的纳米抗体、核酸、表达载体、宿主细胞及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190687A1 (en) * 2000-05-02 2003-10-09 Tong Zhou Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20060269554A1 (en) * 2005-02-02 2006-11-30 Adams Camellia W DR5 antibodies and uses thereof
WO2008004760A1 (fr) * 2006-07-05 2008-01-10 Ajou University Industry-Academic Cooperation Foundation Anticorps se liant spécifiquement à dr5 et composition destinée à prévenir ou traiter des cancers et comprenant cet anticorps

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20030190687A1 (en) * 2000-05-02 2003-10-09 Tong Zhou Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20060269554A1 (en) * 2005-02-02 2006-11-30 Adams Camellia W DR5 antibodies and uses thereof
WO2008004760A1 (fr) * 2006-07-05 2008-01-10 Ajou University Industry-Academic Cooperation Foundation Anticorps se liant spécifiquement à dr5 et composition destinée à prévenir ou traiter des cancers et comprenant cet anticorps

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARK, K. -J. ET AL.: "A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells.", CANCER RESEARCH., vol. 67, no. 15, 1 August 2007 (2007-08-01), pages 7327 - 7334 *

Also Published As

Publication number Publication date
WO2010047509A2 (fr) 2010-04-29
WO2010047509A9 (fr) 2010-09-02

Similar Documents

Publication Publication Date Title
WO2010047509A3 (fr) Anticorps dirigé contre le dr5 présentant une meilleure affinité et une meilleure stabilité, et composition destinée a prévenir ou traiter le cancer et contenant cet anticorps
AR123876A2 (es) Composición farmacéutica de anticuerpos anti-cgrp
PE20141435A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
NZ595235A (en) Compositions and methods for increasing muscle growth
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
WO2007133822A8 (fr) Anticorps anti-gitr destinés au traitement du cancer
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2008063771A3 (fr) Anticorps anti-cd20, et leurs procédés d'utilisation
EA201290173A1 (ru) Антитела против эндоглина
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
PE20120343A1 (es) Anticuerpo anti-cmet que comprende una region bisagra
MX2013010268A (es) Anticuerpos anti-ctla4 humanizados.
PE20130479A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
IN2012DN05101A (fr)
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
NZ575245A (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
NZ618067A (en) Anti-cd100 antibodies and methods for using the same
PE20121645A1 (es) Composiciones y metodos para tratar trastornos inflamatorios

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09822185

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09822185

Country of ref document: EP

Kind code of ref document: A2